Introduction 40
Gonorrhea is a sexually transmitted infection caused by Neisseria gonorrhoeae that infects both 41 men and women. N. gonorrhoeae can establish infections in the urogenital tract, rectum and 42 pharynx, is associated with high morbidity and socioeconomic consequences and remains a 43 public health problem worldwide (1). Complications from untreated gonococcal infections 44 include ectopic pregnancy, infertility in women, and increased risk of HIV infection. Gonorrhea 45 can also be transmitted from mother to neonate and cause blindness or life-threatening 46 disseminated infection (2). Gonococci have become resistant to almost every conventional 47 antibiotic currently in clinical use and we might be entering an era of untreatable gonorrhea (3) 48 (4) (5) (6). Therefore, the need for new treatment options has become a pressing issue. 49 50 An emerging approach to control microbial infections is to target bacterial virulence 51 mechanisms (7) (8). Pathogens have evolved various strategies to escape the innate immune 52 response, including killing by the complement system (9) (10). The complement pathway 53 represents one of the most ancient innate immune systems that has been conserved through 54 evolution, which protects the host against infections. Invading pathogens activate complement 55 either because of differences in surface composition that are recognized by the host as foreign 56 or 'non-self' (alternative and lectin pathways), or through antibody binding (classical pathway). 57
This leads to the initiation of activation; sequential proteolytic cleavage results in the formation 58 of central C3 convertases and opsonization of the target with iC3b, which leads to phagocytosis, 59 release of pro-inflammatory anaphylatoxins (C5a, C3a) that attract white blood cells, and 60 finally formation of a lytic membrane attack complex (MAC) that directly kills Gram-negative 61 pathogens (11). To protect the own body from unwanted complement activation and damage, 62
the complement system is tightly regulated. C4b-binding protein (C4BP) is one of the major 63 of another complement inhibitor, factor H (FH), fused to Fc is efficacious in vitro and in vivo 89
against Streptococcus pyogenes (24), N. gonorrhoeae (7) , N. meningitidis (25) and 90
Haemophilus influenzae (26) and provided the rationale for targeting N. gonorrhoeae-C4BP 91 interactions. 92 93 94
Results 95 C4BP binds Neisseria gonorrhoeae and protects the bacterium from serum-mediated killing 96
Prior work has shown that selected strains of N. gonorrhoeae bind human C4BP (17). We 97 confirmed the previous results using 6 laboratory strains of N. gonorrhoeae (C4BP-binding N. 98 gonorrhoeae 15253, FA1090, 1291 and MS11, and the non-C4BP-binding N. gonorrhoeae F62 99 and 252) either with purified, fluorescently labelled C4BP or with 10% of NHS as a source of 100 C4BP ( Fig. 1A-B ). All C4BP-binding gonococcal strains survived in normal human serum 101 (Suppl. Fig. 1A ) suggesting a role for C4BP in protecting bacteria from complement-mediated 102 lysis. However, some C4BP non-binders may possess other serum resistance mechanisms such 103 as FH recruitment (for example, strain 252; Suppl. Fig. 1D ). Of note, when gonococci were 104 incubated with heat-inactivated human serum (HI NHS), C4BP-binding decreased suggesting 105 that the protein binds not only to PorB but possibly also to complement C3/C4 fragments 106 deposited on the bacterial surface after complement activation, because C4BP does not lose 107 binding capacity and activity at 56°C (Suppl. Fig. 1B-C) (27) . 108 109 Some serum sensitive N. gonorrhoeae strains become serum resistant in vivo as a result of 110 sialylation (28), which leads to binding of FH that similarly to C4BP blocks the complement 111 cascade at the level of C3. Here we show that sialylation of gonococci does not affect C4BP 112 binding (Fig. 1C) while it increases FH deposition on the surface of the pathogens resulting in 113 increased survival, a phenomenon that was expected (Suppl. Fig. 1D-E) . 114
115
We measured C4BP binding to 190 recently isolated gonococcal clinical strains -107 PorB1a 116 and 83 PorB1b isolates -using flow cytometry (Table II) . Laboratory strains 15253 and 252 117 were used as positive and negative controls, respectively for C4BP binding. The cut-off for 118 positivity was fixed at geometrical mean fluorescence intensity (gMFI) + 3xSD of unspecific 7 background of signal obtained for strain 252 that does not bind C4BP. Ninety-six (89.7%) of 120 107 PorB1a isolates bound C4BP, while only 16 (19.3%) of 83 PorB1b strains bound C4BP 121 ( Fig. 1D ). Similar to previously published data, the majority of gonococci binding C4BP belong 122 to the PorB1a subclass (17). Furthermore, no association was found between C4BP binding and 123 anatomical site of isolation ( Fig. 1E) . To promote complement-mediated elimination of serum-resistant N. gonorrhoeae strains taking 136 advantage of their ability to bind C4BP, we created the two fusion proteins C4BPDCCP3-IgG 137 and C4BP(CCP1/2)-IgM by cloning C4BP domains on the backbone of a constant portion of 138 IgG or IgM ( Fig. 2A-B ). C4BP-IgG and C4BP-IgM constructs were prepared in the expression 139 vectors pClaire and pTorsten, respectively. Both fusion proteins were expressed recombinantly 140 in eukaryotic cells and purified using affinity chromatography. Purity and size of the obtained 141 proteins were verified by SDS-PAGE using silver staining ( Fig. 2A-B ). The reduced monomer 142 of C4BP-IgG is about 75 kDa, which assembles as a dimer of 150 kDa. C4BP-IgM has a 143 molecular mass of approximately 52 kDa when reduced, while it during non-reducing conditions appears as a multimer with double bands larger than 500 kDa, similarly to the double 145 band of human control IgM. Since C4BP-IgM is a fusion with IgM CH2-CH4, which 146 commonly assembles in multimers, we analyzed it by electron microscopy. Similarly to human 147 IgM, C4BP-IgM exists as either pentamers or hexamers; the latter was the prevalent form and 148 constituted approximately 80% of recombinantly expressed C4BP-IgM (Fig. 2C) . 149
150
Only C4BP-IgM outcompetes C4BP binding to bacteria 151
Both C4BP-IgG and C4BP-IgM fusion proteins contain CCP1-2 domains of C4BP, which are 152 required for the binding to gonococcal PorB. Using flow cytometry, we confirmed that both 153 fusion proteins bound the laboratory strains that also bound native C4BP, with the exception of 154 MS11 which bound C4BP-IgM but not C4BP-IgG ( Fig. 3A-B ). Of note, sialylation (SA) of 155 bacteria, which occurs in vivo and did not affect native C4BP binding, also did not affect C4BP-156
IgG or C4BP-IgM binding to the bacteria ( Fig. 3D-E ). For gonococcal strain FA1090 we then 157 estimated the binding affinity for the two fusion proteins showing that C4BP-IgM has higher 158 affinity than C4BP-IgG (Kd 2.4 nM versus 981 nM) ( Fig. 3C-F) . This is likely a result of the 159 fact that the multimeric rearrangement of C4BP-IgM results in up to 12 binding sites compared 160 to 2 of the dimeric C4BP-IgG. Analysis of binding to a selection of gonococcal clinical isolates 161 (n=75) using flow cytometry showed a strong correlation between binding of C4BP and that of 162 alpha-1-antitrypsin (a1AT), that were used as negative controls mediated complement 183 deposition ( Fig. 4A-B ). Furthermore, C3b deposition was also observed using mouse serum 184 To determine whether C4BP-IgM also enhanced complement deposition on intact bacteria, we 188 incubated 5 laboratory strains of N. gonorrhoeae with 10% NHS with or without 20 µg/mL 189 C4BP-IgM, and measured surface deposition of complement proteins by flow cytometry. Of 190 note, the concentration of serum used here is 4-fold higher than that used in competition assays 191 these strains were intrinsically more sensitive to complement than 15253 and FA1090; the latter 208 two strains were tested using 20% NHS. Accordingly, killing of MS11 and 1291 occurred in 209 the presence of only 0.25 µg/mL of C4BP-IgM, while a higher concentration (12.5 µg/mL) was 210 required to obtain killing of 15253 and FA1090 over baseline survival in NHS alone. Of note, 211 20 µg/mL C4BP-IgM promoted significant killing of bacteria even when they were sialylated 212 (FA1090 and MS11), while no effect for F62 which did not bind the protein ( Fig. 5E-G) . Indeed, C4BP-IgM binding to gonococci did not affect FH recruitment to the bacterial surface 216 both in the presence or in the absence of LOS sialylation (Suppl. Fig. 1G -H). We also evaluated 217 the efficacy of C4BP-IgM against 26 recent clinical quinolone-resistant isolates of N. 218 gonorrhoeae that all bound C4BP (Table II) . All but two of the isolates (isolates 9 and 53, the latter a FH-binder) were efficiently killed by 20 µg/mL of C4BP-IgM (> 1 log10 reduction in 220 CFU/mL) ( IgM from a patient with myeloma was used as a negative control and did not bind to or promote 235 killing of N. gonorrhoeae laboratory strains (Suppl. Fig. 2A-B ). Treatment of mice infected 236 with either MS11 or FA1090 (6 animals per group) with 5 µg/day of C4BP-IgM intravaginally 237 daily significantly reduced the duration of infection (p<0.0001 versus control groups) in both 238 cases, clearing the bacteria from 50% and 67% of the animals at day 3 for MS11 and FA1090 gonorrhoeae MS11 or FA1090 compared to non-treated controls (p = 0.0034 and p = 0.0049, 245 respectively; Fig. 6C ). Infection with strain F62 that does not bind C4BP was unaffected by 246 C4BP-IgM treatment. In parallel, the myeloma IgM did not affect the course of infection in all 247 groups, indicating that the antibacterial efficacy was related to bacteria-bound C4BP-IgM. 248
Discussion 249
This study identifies C4BP-IgM as a novel antimicrobial fusion protein against N. gonorrhoeae. 250
We tested 190 clinical gonococcal isolates cultured in Sweden in the last 10 years, and we 251 observed that 96/107 (85.7%) PorB1a and 16/83 (19.3%) PorB1b bound C4BP. Binding of 252 C4BP is a strategy used by several strains of N. gonorrhoeae to evade complement, which may 253 provide them a survival advantage in their human host. We have targeted this bacterial immune 254 evasion mechanism by creating a chimeric protein composed of C4BP CCP1-2 and Fc of IgM, 255 which binds to bacteria and promotes complement activation on the microbial surface. We Th1-driven adaptive immune response (34); vaginal lactobacillus strains to counteract 269 gonococcal growth (35); fatty acid derivatives for a fast anti-gonococcal activity targeting 270 membrane disruption (36). Here we present a novel therapeutic approach that targets a virulence 271 mechanism of bacteria -its ability to bind the complement inhibitor C4BP. Initially we created two chimeric proteins combining α-chain domains of C4BP with two types 279 of immunoglobulins, IgG and IgM. In C4BP-IgG full length of C4BP α chain was used with 280 the intent to target different pathogens which possibly bind various domains of C4BP. In 281 contrast, when IgM portion was used we considered only the first two domains of C4BP, 282 essential for C4BP binding to N. gonorrhoeae, since the IgM structure alone is already 283 relatively large. Only C4BP-IgM, but not the C4BP-IgG fusion protein, could compete with the 284 multimeric C4BP for binding to the bacterial surface, even though the inhibition is not 285 complete. We previously documented that the monomeric α-chain of C4BP did not bind to 286
PorB, indicating a requirement for the polymeric form of C4BP to stably interact with PorB 287 (17). Therefore C4BP-IgM was prioritized for further pre-clinical studies. However, it is worth 288 noting that both C4BP fusion proteins could kill gonococci in vitro, although the IgM derivative 289 was more effective on a molar basis (Suppl. Fig. 2C ). C4BP-IgM proved effective in the mouse 290 vaginal colonization model using human FH/C4BP transgenic mice -these mice provide 291 gonococci with human FH and C4BP and raise the threshold for complement-dependent killing 292 by immunotherapeutics as would be encountered in humans. Treatment with C4BP-IgM 293 significantly reduced the duration of infection and bacterial load in animals challenged with the 294 two C4BP-binding gonococcal strains, but not the non-C4BP binding strain, confirming the 295 selectivity of action of C4BP-IgM on gonococci able to bind C4BP, and not because of non-296 specific activation of complement in solution. 297
Interestingly, we documented that binding of C4BP is not affected by sialylation of bacteria, 298 the latter commonly happening after bacterial colonization in vivo and resulting in FH 299 recruitment and protection against complement attack. Likewise, also C4BP-IgM binding is not 300 affected by the presence of sialic acids; however, bactericidal activity of the chimeric protein 301 reduces but it is still significantly effective in killing the sialylated pathogens, suggesting that 302 viability (e.g., PorB) will make the development of resistance unlikely. It is important to note 317 that PorB is essential for gonococcal viability and is constitutively expressed on the surface of 318 gonococci (42) (43). PorB 'escape mutants' that may develop on treatment with FH-IgG Fc or 319 C4BP-IgM are likely to lack the ability to bind to these complement inhibitors and incur a 320 considerable fitness cost; inability to evade complement would enable the host to rapidly clear 321 such mutants that resist these immunotherapeutics.
323
The use of fusion proteins as treatment might have some advantages. Firstly, the chimeric 324 proteins may reduce the use of antibiotics and development of antibiotic resistance. Excessive 325 antibiotic use is also associated with destruction of resident commensal microflora. Indeed, 326 using C4BP-IgM as a treatment, in contrast to antibiotic therapy, would selectively target 327 against those pathogens that developed the ability to escape complement attack by binding 328 C4BP, and that most likely are pathogenic for our body. Therefore, endogenous microflora such 329 as lactobacilli which are not able to recruit the complement inhibitor would not be affected (44). 330
Moreover, C4BP-IgM lacks CCP3 domain which contains all the features responsible for 331 binding to C4b fragments deposited on cell surface after complement activation, therefore 332 C4BP-IgM deposition on C4b -decorated cells will be also excluded. Additionally, C4BP-IgM 333 is not recruited by apoptotic cells because it is lacks β-chain of C4BP that is associated with 334 protein S, which in turn recognizes the exposed phosphatidylserine molecules on dying cells 335 (45). Accordingly, C4BP-IgM did not deposit complement on human erythrocytes or apoptotic 336
cells. 337 338
In conclusion, we have created a novel therapeutic to kill gonococci by targeting a key immune 339 evasion mechanism. C4BP-IgM fusion protein represents an innovative strategy to trigger IgM were cloned in frame with signal peptide sequence into the expression vector pClaire. For 403 C4BP-IgG fusion protein, the construct was prepared cloning the sequence of C4BP lacking 404 CCP3 domain into the expression vector pTorsten; both plasmids were kindly provided by Dr. 405
Brad Spiller (Cardiff University). Chimeric proteins were stably expressed in adherent Chinese 406 hamster ovary cells (CHO; Life Technologies) cultured in serum-free OptiMEM Glutamax at 407 37°C, 5% CO2 collected every second day and replaced for one day with complete medium 408 supplemented with 100 µg/mL hygromycin to maintain the selection of transfected clones. 409 C4BP-IgM was purified from cell culture supernatants by affinity chromatography using anti-410 C4BP antibody MK104 coupled to Affi-Gel 10 (Bio-Rad) as described (23). C4BP-IgG was 411 purified using protein A column (GE Healthcare). Bound proteins were eluted using glycine 412 and 6 M guanidinium chloride. Protein eluate was dialysed against PBS at 4°C and molecular 413 mass and purity were evaluated by silver staining of proteins separated by SDS-PAGE. 414 415
Electron microscopy 416
The multimeric form of C4BP-IgM molecules was analyzed by negative staining and electron 417 microscopy as described previously (59). Human IgM was tested in parallel. Solutions of 1 418 micromolar of proteins were prepared in PBS. Aliquots of 5 µL were adsorbed to carbon-coated 419 grids for 1 min, then washed with two drops of water, and then stained with two drops of uranyl 420 formate. Glow discharge at low pressure in air was used to render the grids hydrophylic. The Bacteria were cultured on chocolate agar plate overnight and sub-cultured on new plates for at 442 least 5 hours with or without CMP-Neu5Ac, the latter in case of sialylated gonococci. Harvested 443 bacteria were then diluted to OD 2 in HBSS ++ and stained with 10 µM CFSE or 1 mM Calcein 444
Violet. Binding of C4BP and C4BP-IgM/C4BP-IgG to bacteria was measured by flow 445 cytometry after incubation at 37°C for 30 min with the purified AlexaFluor 647 or 488 -labelled 446 proteins respectively, diluted in HBSS ++ . To verify the stability of C4BP after heat inactivation 447 of NHS (HI NHS), purified C4BP was treated at 56°C for 30 minutes (C4BP (56°C)) and then 448 tested as above. In some experiments, binding to un-labelled proteins was measured using anti-449 C4BP MK67 followed by AF647 anti-mouse, AF647 anti-hIgM or AF488 anti-hIgG, all diluted in HBSS ++ . For competition assays, increasing concentration of C4BP fusion proteins were 451 added to 2.5% NHS supplemented with 5 µg/mL of AlexaFluor 647-labelled C4BP and with 452
OmCI (23 µg/mL) used as C5-inhibitor preventing cell lysis (60) in GVB ++ followed by 453 incubation at 37°C for 30 minutes with bacteria. In parallel experiments, complement activation 454 Aliquots of 25 µL reaction mixtures were collected at the beginning of the assay (t0) and plated 490 onto chocolate agar in duplicate in 10 -3 dilution. After incubation at 37°C for 30 min (t30) 491 another aliquot of 25 µL was collected, diluted in PBS and plated onto chocolate agar in 492 duplicate (10 -1 or 10 -2 or 10 -3 ). Survival was calculated as the number of viable CFU/mL at t30, 493 while CFU/mL at t0 is referred as starting number of bacteria in each graph. In some cases, 494 survival was calculated as percentage of the number of viable colonies at t30 relative to t0. Serum 495 resistant strains were defined as having survival greater than 50%. were challenged with 4.1 x 10 7 CFU/10 μL for strain MS11, 3.6 x 10 7 CFU/10 μL for strain FA1090 and 3.2 x 10 7 CFU/10 μL for strain F62, all at day 0. Mice were then treated intravaginally daily with 5 μg/d of C4BP-IgM (solid black line with opened circles), or 5 μg/d of 'nonspecific' IgM (solid grey line with triangles) or 10 μL PBS (vehicle control; dotted line with black squares) from day 1 to day 8. Vaginas were swabbed daily to enumerate CFU. A) Kaplan-Meier analysis of time to clearance of infection. Group comparison was done using Logrank (Mantel-Cox) test. Significance for MS11 and FA1090 were set at 0.0167 (Bonferroni's correction for 3 groups). B) Log 10 CFU versus time (days). Symbols indicate mean values ± SEM. C) Bacterial burdens consolidated over time (area under the curve of Log 10 CFU analysis) for the three groups. Median values are shown for each group. For strains MS11 and FA1090 treatment groups were compared using the non-parametric Kruskal-Wallis equality of populations rank test. The χ2 with ties (two degrees of freedom) for MS11 and FA1090 were 11.56 (p = 0.0004) and 11.42 (p = 0.0005), respectively. Pairwise comparisons across groups were made with Dunn's post-hoc test (p = 0.0034 and p = 0.0049 C4BPIgM treatment versus PBS, for MS11 and FA1090 respectively). AUC comparisons across the two treatment groups with strain F62 was made with the two-sample Wilcoxon rank-sum (Mann-Whitney) test.
